Treatment of proteinuric idiopathic glomerulonephritides in adults: A retrospective survey

The American Journal of Medicine

Volumn 85, Issue 3 C, 1988, Pages 315-326

  Schena, F Paolo ^a   Cameron, J Stewart ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPYRIDAMOLE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; WARFARIN;

ADULT; GLOMERULONEPHRITIS; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLOMERULONEPHRITIS; HUMAN; PREDNISONE; PROTEINURIA; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0023736922     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(88)90580-3     Document Type: Article

References (103)

1. Demography of dialysis and transplantation in Europe, 1984
2. Trends in the US end-stage renal disease population: 1973–1983
3. Regional program for the study of glomerulonephritis
4. Renal disease in China; an overview
5. Some characteristics related to the incidence of cardiovascular disease and death: Framingham study, 18 years follow-up
6. Mesangial proliferative glomerulonephritis
7. Nephrotic syndrome with glomerular mesangial IgM deposits
8. Nephrotic syndrome with mesangial-cell proliferation in children—a distinct entity?
9. IgM associated primary diffuse mesangial proliferative glomerulonephritis
10. Significance of mesangial IgM deposition in “minimal change” nephrotic syndrome
11. No evidence of a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome
12. The clinical significance of mesangial IgM deposits and mesangial hypercellularity in minimal change nephrotic syndrome
13. Controlled trial of prednisone in adult patients with the nephrotic syndrome
14. Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis
15. Minimal change nephrosis in adults
16. Lipoid nephrosis in 31 adult patients: renal biopsy study by light, electron, and fluorescence microscopy with experience in treatment
17. Clinicopathological correlations in the nephrotic syndrome due to primary renal disease
18. Adult lipoid nephrosis; clinicopathological correlations
19. Therapy of the idiopathic nephrotic syndrome with alternate day steroids
20. Minimal change glomerular disease in malaysian adults and use of alternate day steroid therapy
21. Adult-onset minimal change nephrotic syndrome: a long-term follow-up
22. Proteinuric glomerular disease in adults: cumulative life tables over twenty years
23. Focal glomerular sclerosis: contrasting clinical patterns in children and adults
24. Mesangial proliferative glomerulonephritis with IgM deposits
25. Focal sclerosing glomerulonephropathy
26. The long-term prognosis of patients with focal segmental glomerulosclerosis
27. Focal glomerulosclerosis: natural history and treatment
28. Evaluation and correlation of clinical and histological features of focal segmental glomerulosclerosis
29. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy
30. Traitement par le chlorambucil et l'azathioprine dans les glomérulonéphrites primitives
31. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis
32. A controlled study of short-term prednisone treatment in adults with membranous nephropathy
33. Prognosis and treatment of membranous nephropathy
34. The clinical course of idiopathic membranous nephropathy
35. Treatment of idiopathic membranous nephropathy
36. Idiopathic membranous nephropathy
37. Membranous nephropathy: its relative benignity in women
38. The long-term outcome of idiopathic membranous nephropathy
39. Long-term prognosis of idiopathic membranous glomerulonephritis
40. The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults
41. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis
42. Membranoproliferative glomerulonephritis
43. Results of a controlled drug trial in membranoproliferative glomerulonephritis
44. The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function
45. Idiopathic mesangiocapillary glomerulonephritis: comparison of types I and II in children and adults and long-term prognosis
46. Treatment of chronic glomerulonephritis with a combination of indomethacin and cyclophosphamide
47. Type 3 membranoproliferative glomerulonephritis
48. Plasma exchange in the treatment of mesangiocapillary glomerulonephritis
49. Relapsing nephrotic syndrome in childhood
50. Natural history and outcome of the nephrotic syndrome
51. Glomerulonephritis in Indonesia
52. The primary nephrotic syndrome in children
53. Lipoid nephrosis an approach to the clinicopathologic analysis and dismemberment of idiopathic nephrotic syndrome with minimal glomerular changes
54. Long-term outcome for children with minimal change nephrotic syndrome
55. Current concepts: the treatment of nephrosis
56. Long-term results of steroid therapy in adults with idiopathic nephrotic syndrome
57. Controlled trial of methylprednisolone pulses and low dose oral prednisone for the minimal change nephrotic syndrome
58. Steroid resistant nephrotic syndrome: a review of the treatment of focal segmental glomerulosclerosis in children
59. Treatment of chronic glomerulonephritis with indomethacin
60. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome
61. Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study
62. Analgesic and non-steroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study
63. Pathogenesis of hypertension in glomerular disease
64. Traitement des syndromes néphrotiques corticorésistants de l'adulte
65. Cyclosporin in the treatment of idiopathic nephrotic syndrome in children
66. Idiopathic membranous glomerulonephritis in adults; remission following steroid therapy
67. Prognosis in steroid-treated idiopathic nephrotic syndrome in adults: analysis of major predictive factors after ten-years follow-up
68. Membranous glomerulonephritis: longterm serial observations on clinical course and morphology
69. Corticosteroid therapy is beneficial in adults with idiopathic membranous glomerulopathy
70. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy
71. Prednisone treatment in non nephrotic patients with idiopathic membranous nephropathy
72. Clinicopathologic correlations in idiopathic nephrotic syndrome with membranous nephropathy
73. Controlled trial of azathioprine and prednisone in chronic renal disease
74. Membranous glomerulonephritis: evolution of clinical and pathologic features
75. The natural history of membranous glomerulonephropathy
76. The natural history and treatment of membranous glomerulonephritis
77. Membranous nephropathy: long-term follow-up and association with neoplasia
78. Membranous glomerulonephropathy there is no significant effect of treatment with corticosteroids
79. Relapsing idiopathic membranous nephropathy
80. Survival in idiopathic membranous glomerulonephritis
81. Long-term prognosis of membranous nephropathy
82. Membraneous nephropathy should be treated with cytotoxic drugs
83. Poor response of idiopathic membranous glomerulonephritis to alternate courses of steroids and chlorambucil
84. Analysis of 260 cases of membranous glomerulonephritis in renal biopsy material
85. Natural history of lipoid nephrosis and of membranous glomerulonephritis
86. Les glomérulopathies “extra-membraneuse” (G.E.M.)
87. Pathology of membranous nephropathy
88. Pathogenesis and treatment of membranous nephropathy
89. Strong association of idiopathic membranous glomerulonephritis with HLA-DR2 and MT1 in Japan
90. Strong association between idiopathic membranous nephropathy and HLA-DRw3
91. Strong association of idiopathic membranous nephropathy with HLA-DR3 and MT2 without involvement of HLA-B18 and no association to BfFI
92. The natural history of membranous nephropathy in the West of Scotland
93. What is the basis for the use of steroids in the treatment of idiopathic membranous nephropathy?
94. The prognosis value of some clinical and histological parameters in membranoproliferative glomerulonephritis
95. Membranoproliferative glomerulonephritis
96. Combined report on regular dialysis and transplantation in Europe
97. Idiopathic membranoproliferative (mesangiocapillary) glomerulonephritis: a clinicopathologic study
98. A prospective randomized trial in the use of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis
99. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis
100. Childhood membranoproliferative glomerulonephritis: an approach to management
101. Report of the International Study of Kidney Disease in Children: Alternate day steroid therapy in membranoproliferative glomerulonephritis: a randomized controlled clinical trial
102. Immunosuppressive therapy in primary glomerulonephritis (pros)